Alfredo Tartarone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2806539/publications.pdf

Version: 2024-02-01

567247 477281 60 935 15 29 citations h-index g-index papers 60 60 60 1555 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Cardiovascular risk of smoking and benefits of smoking cessation. Journal of Thoracic Disease, 2020, 12, 3866-3876.	1.4	131
2	Support Ellagic Acid Therapy in Patients with Hormone Refractory Prostate Cancer (HRPC) on Standard Chemotherapy Using Vinorelbine and Estramustine Phosphate. European Urology, 2005, 47, 449-455.	1.9	88
3	Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. Future Oncology, 2019, 15, 2423-2433.	2.4	73
4	Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. European Journal of Haematology, 2007, 79, 53-58.	2.2	71
5	Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer, 2013, 81, 328-336.	2.0	49
6	The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy. Critical Reviews in Oncology/Hematology, 2013, 86, 42-51.	4.4	46
7	Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. Therapeutic Advances in Respiratory Disease, 2015, 9, 242-250.	2.6	42
8	Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management. Future Oncology, 2015, 11, 2043-2048.	2.4	35
9	COVID-19 and cancer care: what do international guidelines say?. Medical Oncology, 2020, 37, 80.	2.5	29
10	Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: a retrospective study. Translational Lung Cancer Research, 2021, 10, 995-1006.	2.8	27
11	Progress and challenges in the treatment of small cell lung cancer. Medical Oncology, 2017, 34, 110.	2.5	25
12	Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. European Journal of Clinical Pharmacology, 2012, 68, 505-512.	1.9	22
13	Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK–Positive Non–Small Cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2016, 17, e173-e177.	2.6	22
14	CD38 expression does not change in B-cell chronic lymphocytic leukemia. Blood, 2002, 100, 3052-3052.	1.4	20
15	Possible applications of circulating tumor cells in patients with non small cell lung cancer. Lung Cancer, 2017, 107, 59-64.	2.0	17
16	A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. Translational Lung Cancer Research, 2021, 10, 80-92.	2.8	17
17	Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget, 2016, 7, 40085-40094.	1.8	17
18	Prevention of high-dose melphalan-induced mucositis by cryotherapy. Leukemia and Lymphoma, 2005, 46, 633-634.	1.3	16

#	Article	IF	CITATIONS
19	Linezolid-induced bradycardia: a case report. International Journal of Antimicrobial Agents, 2004, 23, 412-413.	2.5	15
20	Long-term survival in small cell lung cancer: a case report and review of the literature. Future Oncology, 2014, 10, 523-528.	2.4	15
21	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: What Do We Know?. Therapeutic Drug Monitoring, 2010, 32, 669-672.	2.0	14
22	Anal metastasis from breast cancer: a case report and review of the literature. Future Oncology, 2012, 8, 333-336.	2.4	10
23	Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity. Oncology Letters, 2013, 5, 1741-1743.	1.8	10
24	Smoking burden, MPOWER, future tobacco control and real-world challenges in China: reflections on the WHO report on the global tobacco epidemic 2021. Translational Lung Cancer Research, 2022, 11, 117-121.	2.8	10
25	Guillain-Barré Syndrome Complicating Mobilization Therapy in a Case of B-cell Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2004, 45, 1489-1490.	1.3	9
26	Somatostatin Analog Therapy in Small Cell Lung Cancer. Seminars in Nuclear Medicine, 2016, 46, 239-242.	4.6	9
27	Focus on lung cancer screening. Journal of Thoracic Disease, 2020, 12, 3815-3820.	1.4	9
28	Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. Journal of Thoracic Disease, 2017, 9, S1391-S1396.	1.4	8
29	Treatment of performance status 2 patients with advanced non-small-cell lung cancer: what we know and what we don't know. Future Oncology, 2009, 5, 837-841.	2.4	8
30	When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs. Expert Review of Anticancer Therapy, 2015, 15, 761-763.	2.4	7
31	Fibrinolytic, platelet and monocyte variables in homozygous familial hypercholesterolemia. The effect of a regular plasma cholesterol removal by LDL-apheresis. Fibrinolysis, 1993, 7, 63-64.	0.5	6
32	Late and Long-lasting Response in an Adult Chronic Idiopathic Thrombocytopenic Purpura after Extended Course of Rituximab. Leukemia and Lymphoma, 2003, 44, 561-562.	1.3	6
33	Primary Gastric Lymphoma for Stage I/II1 E: Operative and Conservative Management in Retrospective Data from 71 Cases. Leukemia and Lymphoma, 2003, 44, 1259-1261.	1.3	5
34	Is there a role for immunotherapy in malignant pleural mesothelioma?. Medical Oncology, 2018, 35, 98.	2.5	5
35	Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. Medical Oncology, 2012, 29, 3198-3201.	2.5	4
36	Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?. Medical Oncology, 2014, 31, 78.	2.5	4

3

#	Article	IF	Citations
37	Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II study. Tumori, 2005, 91, 131-4.	1.1	4
38	Role of Parenteral Nutrition in Cancer Patients Undergoing High-Dose Chemotherapy Followed by Autologous Peripheral Blood Progenitor Cell Transplantation. Tumori, 2005, 91, 237-240.	1.1	3
39	Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. Medical Oncology, 2012, 29, 1599-1605.	2.5	3
40	Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, \$1359-\$1363.	1.4	3
41	Oral anticancer therapy project: Clinical utility of a specific home care nursing programme on behalf of Italian Association of Medical Oncology (AIOM). Journal of Clinical Nursing, 2020, 29, 119-129.	3.0	3
42	Pulmonary Blastoma after Liver Transplant: A Case Report. Tumori, 2002, 88, 173-175.	1.1	2
43	Improvement of B-Cell Chronic Lymphocytic Leukemia During Haemodialysis: Possible Role for Endogenous Production of Factors Involved in Angiogenesis and Apoptosis?. Leukemia and Lymphoma, 2003, 44, 1263-1265.	1.3	2
44	Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy. The Hematology Journal, 2004, 5, 453-455.	1.4	2
45	Reflections About Off-label Use of Anticancer Drugs. Therapeutic Drug Monitoring, 2012, 34, 604.	2.0	2
46	Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. Future Oncology, 2013, 9, 127-133.	2.4	2
47	Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management., 2022, 39, 107.		2
48	Quantitative Evaluation of CD52 Expression in B-Cell Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2003, 44, 1255-1257.	1.3	1
49	Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature. Future Oncology, 2010, 6, 1937-1940.	2.4	1
50	New cancer drugs: the Italian unsatisfactory solution. Annals of Oncology, 2014, 25, 1448.	1.2	1
51	Octogenarians may benefit from stage-specific small cell lung cancer treatment. Translational Lung Cancer Research, 2021, 10, 3973-3982.	2.8	1
52	Management of oligoprogression in non-small cell lung cancer patients. Medical Oncology, 2022, 39, 56.	2.5	1
53	Role of parenteral nutrition in cancer patients undergoing high-dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation. Tumori, 2005, 91, 237-40.	1.1	1
54	The Predictive Role of HER2 Overexpression in Early Breast Cancer. Journal of Clinical Oncology, 2003, 21, 3179-3180.	1.6	0

#	Article	IF	Citations
55	Response to de Gramont regimen in small cell lung cancer: a case report. Lung Cancer, 2004, 43, 375-376.	2.0	O
56	Contractile Reserve As a Marker of Preclinical Cardiotoxicity. Journal of Clinical Oncology, 2010, 28, e769-e769.	1.6	0
57	Focus on maintenance therapy in non-small-cell lung cancer. Future Oncology, 2015, 11, 189-192.	2.4	O
58	The era of a "liquid biopsy―may be on the horizon in non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, S1322-S1322.	1.4	0
59	The importance both of early diagnosis and smoking cessation in the battle against lung cancer. Journal of Thoracic Disease, 2020, 12, 3813-3814.	1.4	0
60	Pulmonary blastoma after liver transplant: a case report. Tumori, 2002, 88, 173-5.	1.1	O